Ann: Photosoft efficiently destroys ovarian cancer cells in vitro, page-42

Excerpt from article on * today:

Of the 36 biotech companies in our table below, 19 are ahead over the past 12 months. Star performer Invion (ASX:IVX)is up 1750 per cent for the year to 3.7c.

Its share price went as high as 4.9c last week when the company gave an update on tests for its Photosoft cancer treatment, which is designed to destroy ovarian cancer cells.

Speaking to * about that news last week, chief executive Greg Collier said oncology — the study of tumours — was now Invion’s “total focus”.

He pointed to a research and development partnership with the Cho Group, which means the company doesn’t need to raise capital to continue with its drug development process. The company is next looking at animal studies as part of further ovarian cancer treatment tests.